Article ; Online: B-cell targeted therapeutics in clinical development.
2013 Volume 15 Suppl 1, Page(s) S4
Abstract: B lymphocytes are the source of humoral immunity and are thus a critical component of the adaptive ... immune system. However, B cells can also be pathogenic and the origin of disease. Deregulated B-cell function ... arthritis, and multiple sclerosis. B cells contribute to pathological immune responses through the secretion ...
| Abstract | B lymphocytes are the source of humoral immunity and are thus a critical component of the adaptive immune system. However, B cells can also be pathogenic and the origin of disease. Deregulated B-cell function has been implicated in several autoimmune diseases, including systemic lupus erythematosus, rheumatoid arthritis, and multiple sclerosis. B cells contribute to pathological immune responses through the secretion of cytokines, costimulation of T cells, antigen presentation, and the production of autoantibodies. DNA-and RNA-containing immune complexes can also induce the production of type I interferons, which further promotes the inflammatory response. B-cell depletion with the CD20 antibody rituximab has provided clinical proof of concept that targeting B cells and the humoral response can result in significant benefit to patients. Consequently, the interest in B-cell targeted therapies has greatly increased in recent years and a number of new biologics exploiting various mechanisms are now in clinical development. This review provides an overview on current developments in the area of B-cell targeted therapies by describing molecules and subpopulations that currently offer themselves as therapeutic targets, the different strategies to target B cells currently under investigation as well as an update on the status of novel therapeutics in clinical development. Emerging data from clinical trials are providing critical insight regarding the role of B cells and autoantibodies in various autoimmune conditions and will guide the development of more efficacious therapeutics and better patient selection. |
|---|---|
| MeSH term(s) | Antibodies, Monoclonal/pharmacology ; Antibodies, Monoclonal/therapeutic use ; Antibodies, Monoclonal, Humanized/pharmacology ; Antibodies, Monoclonal, Humanized/therapeutic use ; Antibodies, Monoclonal, Murine-Derived/pharmacology ; Antibodies, Monoclonal, Murine-Derived/therapeutic use ; Autoimmune Diseases/drug therapy ; Autoimmune Diseases/immunology ; Autoimmune Diseases/pathology ; B-Cell Activating Factor/antagonists & inhibitors ; B-Cell Activating Factor/drug effects ; B-Lymphocytes/drug effects ; B-Lymphocytes/pathology ; Humans ; Immunologic Factors/pharmacology ; Immunologic Factors/therapeutic use ; Patient Selection ; Rituximab |
| Chemical Substances | Antibodies, Monoclonal ; Antibodies, Monoclonal, Humanized ; Antibodies, Monoclonal, Murine-Derived ; B-Cell Activating Factor ; Immunologic Factors ; Rituximab (4F4X42SYQ6) ; belimumab (73B0K5S26A) ; tabalumab (PQP8VH3MJW) |
| Language | English |
| Publishing date | 2013-04-04 |
| Publishing country | England |
| Document type | Journal Article ; Review |
| ZDB-ID | 2107602-9 |
| ISSN | 1478-6362 ; 1478-6354 |
| ISSN (online) | 1478-6362 |
| ISSN | 1478-6354 |
| DOI | 10.1186/ar3906 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.A 5490: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.